GSK, Genmab Set “Ambitious” Development Plan For HuMax-CD20
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.
You may also be interested in...
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
ODAC To Evaluate Strength Of Objective Response Rate Of Arzerra In CLL
Meeting at the ASCO annual meeting, FDA’s oncology panel will consider whether the effect sizes of surrogate endpoints observed in patients refractory to two drugs justify accelerated approval of GSK/Genmab’s ofatumumab.